# Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)

> **NCT04450654** · PHASE2 · WITHDRAWN · sponsor: **University of Washington**

## Conditions studied

- Immune-Mediated Necrotizing Myopathy

## Interventions

- **DRUG:** Gamunex-C
- **DRUG:** Albumin

## Key facts

- **NCT ID:** NCT04450654
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-05
- **Primary completion:** 2022-07-25
- **Final completion:** 2022-07-25
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No Participants Enrolled
- **Last updated:** 2022-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04450654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04450654, "Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04450654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*